This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of participants with unresectable Hepatocellular Carcinoma (HCC, a.k.a. liver cancer).

Eye90 is comprised of tiny glass beads containing yttrium-90 (Y90), a radioactive material. The beads are delivered in and around the tumor(s) through a tiny catheter placed through the artery of the groin or wrist and into one or more branches of the artery of the liver under x-ray camera guidance.

This study is being done to determine if we can lower the chance of diffuse large B-cell lymphoma (DLBCL) growing or spreading by adding treatment to the usual therapy.

This clinical trial is for adult participants who have triple-negative breast cancer (TNBC).
   
The purpose of this study is to evaluate the safety and effectiveness of the study drug datopotamab deruxtecan (also called Dato-DXd) given in combination with another investigational drug called durvalumab.
   
Dato-DXd and Durvalumab are experimental, which means that they are being tested and are not approved by the United States Food and Drug Administration (FDA).
   

This clinical trial is for men and women with myelofibrosis.
   
The purpose of this study is to test the safety and tolerability of INCB057643 in combination with ruxolitinib on people with myelofibrosis. 
   

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

Camizestrant is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA). 

The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with large B-cell lymphoma and follicular lymphoma approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.

Axicabtagene ciloleucel is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA). 

The LimFlow™ System, PMA P220025, received U.S. Food and Drug Administration (FDA) approval on September 11, 2023. The purpose of this post-approval study is to provide additional information on a device designed to create a connection between the artery and vein in the Below The Knee (BTK) vascular system, using a minimally invasive approach. This procedure is only indicated for patients with “chronic limb-threatening ischemia” who are not likely to be helped with standard operations or procedures and are at risk of major amputation.

This SafeHeal study is designed to assess the overall safety of the low anterior resection (LAR) standard of care cancer treatment by establishing a definition of major complications. The current literature on standard of care reports adverse events/complications but does not provide a single endpoint that can be used to compare the safety of LAR cancer treatment to alternative therapies or treatments. This study will allow for the establishment of a new single safety endpoint for LAR standard-of-care cancer treatment.
   

 This study is evaluating the initial safety and efficacy of local injections of E-CEL UVEC cells, which are genetically engineered (pro-survival gene, E4ORF1+), human umbilical vein endothelial cells, as an experimental treatment of patients with chronic anal fissure (CAF) who have failed medical therapy (i.e., topical vasodilators ± botulinum injection). 

Experimental means that E-CEL UVEC is not approved by the U.S Food and Drug Adminstration.